Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
CNS: Fiscal 2004 revenue expected to increase 10%-13% to $85 mil.-$90 mil., President & CEO Marti Morfitt tells analysts during March 20 conference call. Morfitt projects sales growth should come from four areas noting CNS' domestic Breathe Right nasal strip, FiberChoice businesses will increase 2%-4%, while international sales should rise 10%-18%. CNS anticipates Breathe Right Snore Relief Throat Spray, which launched in mid-2002, will grow another $1 mil.-$3 mil. in sales over FY 2003, and the firm's new Breathe Right Vapor Shot! vaporizer is expected to add $4 mil.-$7 mil. in new product revenue (1"The Tan Sheet" March 17, 2003, p. 19). CNS plans to increase domestic Breathe Right ad expenditure by 10% to $22 mil., to be "split between our snoring message and our nasal congestion message," Morfitt says...
You may also be interested in...
People In Brief
Perrigo promotes in pricing, planning
Zila Saw Palmetto Inventory Loss Offset By Strong Ester-C Sales
A roughly $300,000 decrease in the value of Zila's saw palmetto inventory negatively impacted the firm's fourth quarter earnings in fiscal 2002
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC